 Patients will receive freshly prepared MB-CART19.1 on day 0, corresponding to day 12 48 hours of manufacturing, at a dose of 2x10e6 2x10e7kg MB-CART19.1 T cells as defined in the study design section. The appropriate volume for the target cell dose will be drawn up and given as an IV injection over 30 minutes through a large vein peripherally or centrally. 